Next Article in Journal
Tumor Microenvironment in the Brain
Next Article in Special Issue
Immune Response to Sipuleucel-T in Prostate Cancer
Previous Article in Journal
Desmoid Tumors in Pregnant and Postpartum Women
Previous Article in Special Issue
Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(1), 193-217;

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

Biologics Safety and Disposition, Preclinical Safety, Translational Sciences, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Werk Klybeck, Klybeckstraße 141, Basel CH-4057, Switzerland
Institute of Immunology, Medical Faculty, University of Technology Dresden, Fetscherstraße 74, Dresden 01307, Germany
Department of Urology, Medical Faculty, University of Technology Dresden, Fetscherstraße 74, Dresden 01307, Germany
Author to whom correspondence should be addressed.
Received: 13 January 2012 / Revised: 14 February 2012 / Accepted: 16 February 2012 / Published: 22 February 2012
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
Full-Text   |   PDF [243 KB, uploaded 22 February 2012]


Prostate cancer (PCa) is the most common noncutaneous cancer diagnosis and the second leading cause of cancer-related deaths among men in the United States. Effective treatment modalities for advanced metastatic PCa are limited. Immunotherapeutic strategies based on T cells and antibodies represent interesting approaches to prevent progression from localized to advanced PCa and to improve survival outcomes for patients with advanced disease. CD8+ cytotoxic T lymphocytes (CTLs) efficiently recognize and destroy tumor cells. CD4+ T cells augment the antigen-presenting capacity of dendritic cells and promote the expansion of tumor-reactive CTLs. Antibodies mediate their antitumor effects via antibody-dependent cellular cytotoxicity, activation of the complement system, improving the uptake of coated tumor cells by phagocytes, and the functional interference of biological pathways essential for tumor growth. Consequently, several tumor-associated antigens (TAAs) have been identified that represent promising targets for T cell- or antibody-based immunotherapy. These TAAs comprise proteins preferentially expressed in normal and malignant prostate tissues and molecules which are not predominantly restricted to the prostate, but are overexpressed in various tumor entities including PCa. Clinical trials provide evidence that specific immunotherapeutic strategies using such TAAs represent safe and feasible concepts for the induction of immunological and clinical responses in PCa patients. However, further improvement of the current approaches is required which may be achieved by combining T cell- and/or antibody-based strategies with radio-, hormone-, chemo- or antiangiogenic therapy. View Full-Text
Keywords: antibodies; dendritic cells; immunotherapy; prostate cancer; T cells antibodies; dendritic cells; immunotherapy; prostate cancer; T cells
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Kiessling, A.; Wehner, R.; Füssel, S.; Bachmann, M.; Wirth, M.P.; Schmitz, M. Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer. Cancers 2012, 4, 193-217.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top